New York, New York 10032

  • MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier

Purpose:

Carriers of the m.3242A>G mutation often have clinical symptoms which can include migraines, seizures, strokes, hearing loss, balance issues, gastrointestinal issues, and many other symptoms. The investigators would like to learn more about these disorders and have designed a "Natural History Study" to monitor these conditions over time so that physicians and scientists can not only understand the problems that patients have, but work on developing treatments. The focus of the current work is to evaluate known mutation carriers of the m.3243A>G (mitochondrial DNA) and their maternal relatives (carrier status not a requirement for participation). Paternal relatives will serve as controls. This study involves no treatment.


Study summary:

The purpose of this study is to investigate the neurological and biochemical consequences of the m.3243 A>G mutation. Mitochondria are the powerhouses of the cell and are controlled by nuclear genetic material (DNA) and mitochondrial (mt) DNA. Mitochondrial DNA mutations impair mitochondrial function, and cause cellular energy failure. These mutations, when present in high abundance, cause neurological signs and symptoms that are clinically obvious. The investigators hypothesize that these mutations, when present in lesser abundance, will cause measurable alterations in the patient's neuropsychological profile and cerebral energy profile. This study does not involve any experimental or approved therapy. The investigators will evaluate the patient's condition with blood/urine tests, neurological exam, MRI/MRS, questionnaires, motor skills functioning, serum and urine biomarkers, and genetic testing.


Criteria:

Inclusion Criteria: Known carrier of a the m.3243 A>G mitochondrial mutation, ,or Maternally related to someone who carries the m.3243A>G mitochondrial mutation. A family member who is not maternally related to someone who carries the m.3243A>G mitochondrial mutation Exclusion Criteria: - Younger than 4 years of age - No confirmed m.3243 A>G mitochondrial DNA mutation in the family.


NCT ID:

NCT01532791


Primary Contact:

Principal Investigator
Darryl De Vivo, MD
dcd1@columbia.edu

Kris Engelstad, MS
Phone: 2123056834
Email: ke4@cumc.columbia.edu


Backup Contact:

Email: dcd1@cumc.columbia.edu
Darryl De Vivo, MD
Phone: 2123055244


Location Contact:

New York, New York 10032
United States

Kris Engelstad, MS
Phone: 212-305-6834
Email: ke4@cumc.columbia.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: December 08, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.